Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.40 USD
Change Today +0.0206 / 5.42%
Volume 73.1K
NBY On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

novabay pharmaceuticals inc (NBY) Snapshot

Open
$0.39
Previous Close
$0.38
Day High
$0.42
Day Low
$0.38
52 Week High
06/4/15 - $1.05
52 Week Low
08/24/15 - $0.17
Market Cap
29.5M
Average Volume 10 Days
365.0K
EPS TTM
$-0.33
Shares Outstanding
73.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVABAY PHARMACEUTICALS INC (NBY)

Related News

No related news articles were found.

novabay pharmaceuticals inc (NBY) Related Businessweek News

No Related Businessweek News Found

novabay pharmaceuticals inc (NBY) Details

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes topical non-antibiotic antimicrobial products for the eye care market. It operates through four segments: Dermatology, Ophthalmology, Urology, and Wound Care. The company focuses on addressing the unmet therapeutic needs of the topical anti-infective market. Its commercial products include the Neutrox family of products, including Avenova for the eye care market; Neutrophase for wound care; and CelleRx for the dermatology market. The company’s products under development stage consist of Aganocide compounds, which are novel, synthetic anti-infectives designed to mimic the body’s defense against infection and developed to treat and prevent a range of local, non-systemic infections with a low likelihood of developing bacterial resistance. It has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds that cover various dermatological conditions. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

32 Employees
Last Reported Date: 03/26/15
Founded in 2000

novabay pharmaceuticals inc (NBY) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $478.5K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $318.8K
Senior Vice President of Business and Corpora...
Total Annual Compensation: $281.3K
Compensation as of Fiscal Year 2014.

novabay pharmaceuticals inc (NBY) Key Developments

Novabay Pharmaceuticals Signs Distribution Agreement to Make Avenova Available in New Zealand

NovaBay Pharmaceuticals, Inc. announced that the company's breakthrough prescription daily eyelid and lash hygiene product, Avenova, will be marketed in New Zealand through a partnership with Ophthalmic Instrument Company.

NovaBay Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

NovaBay Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter ended June 30, 2015. For the quarter, the company reported total net sales were $1,008,000 compared to $123,000 a year ago. The increase was due to the sales of Avenova, which was commercially launched in August 2014, partially offset by a decrease in collaboration revenue. Operating loss was $4,859,000 compared to $3,786,000 a year ago. Loss before provision for income taxes was $4,881,000 compared to $2,932,000 a year ago. Net loss was $4,887,000 or $0.07 basic and diluted per share compared to $2,942,000 or $0.06 basic and diluted per share a year ago. The higher net loss reflects higher spending on sales and marketing activities for Avenova, partially offset by lower spending on research and development due to clinical activities underway in 2014. For the six months, the company reported total net sales were $1,546,000 compared to $411,000 a year ago. Operating loss was $9,520,000 compared to $7,864,000 a year ago. Loss before provision for income taxes was $9,519,000 compared to $6,497,000 a year ago. Net loss was $9,527,000 or $0.16 basic and diluted per share compared to $6,507,000 or $0.14 basic and diluted per share a year ago.

NovaBay Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 13, 2015

NovaBay Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBY:US $0.40 USD +0.0206

NBY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NBY.
View Industry Companies
 

Industry Analysis

NBY

Industry Average

Valuation NBY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.5x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVABAY PHARMACEUTICALS INC, please visit www.novabaypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.